Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
15.86
+0.38 (+2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus Inc
< Previous
1
2
3
4
Next >
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Evolus
Via
Business Wire
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
July 27, 2023
Via
Investor Brand Network
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
November 07, 2023
From
Evolus
Via
Business Wire
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
November 06, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in November Investor Conferences
November 01, 2023
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2023 Results
October 25, 2023
From
Evolus
Via
Business Wire
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in September Conferences
August 29, 2023
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
August 23, 2023
From
Evolus
Via
Business Wire
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
August 21, 2023
From
Evolus
Via
Business Wire
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
August 08, 2023
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Via
Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
August 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2023 Results and Provides Business Update
August 02, 2023
From
Evolus
Via
Business Wire
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
July 27, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
July 26, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus to Report Second Quarter 2023 Results and Provide Business Update
July 19, 2023
From
Evolus
Via
Business Wire
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
June 29, 2023
From
Evolus
Via
Business Wire
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
June 22, 2023
From
Evolus
Via
Business Wire
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
June 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2023 Results and Provides Business Update
May 09, 2023
From
Evolus
Via
Business Wire
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
May 09, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus to Report First Quarter 2023 Results and Provide Business Update
May 05, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
February 27, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.